Trial Outcomes & Findings for A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy (NCT NCT01859741)

NCT ID: NCT01859741

Last Updated: 2020-09-09

Results Overview

To determine the MTD of tarextumab when administered on Day 1 of each 21 day cycle along with etoposide 100 mg/m2 on Days 1, 2 and 3, and cisplatin 80 mg/m2 or carboplatin area under the curve (AUC) of 5 mg/mL•min on Day 1 in subjects with untreated extensive stage small cell lung cancer. DLT evaluable population includes all subjects who received at least 1 partial dose of OMP-59R5 during the Phase 1b dose escalation portion of the study including the carboplatin cohort and who had completed Day 21 cycle of 1 OMP-59R5 administration or had discontinued due to drug-related toxicity.

• Recruitment status: TERMINATED
• Study phase: PHASE1/PHASE2
• Target enrollment: 172 participants
• Primary outcome timeframe: Up to 1 year in absence of unacceptable toxicity or disease progression.
• Results posted on: 2020-09-09

Participant Flow

Phase 1b: Approximately 30 subjects were planned. A total of 27 subjects were enrolled. Phase 2: Approximately 135 subjects were planned to be randomized. A total of 145 subjects were enrolled/randomized. Total: 172 subjects were enrolled/randomized (Phase 1b and Phase 2)

Participant milestones

Measure	P1B: OMP-59R5 5mg/kg + ETO + CIS Cohort 1: Subjects receive OMP-59R5 5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 7.5 mg/kg + ETO + CIS Cohort 2: Subjects receive OMP-59R5 7.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 10 mg/kg + ETO + CIS Cohort 3: Subjects receive OMP-59R5 10 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3 and cisplatin 80 mg/m2 on Day 1).	P1B: OMP-59R5 12.5 mg/kg + ETO + CIS Cohort 4: Subjects receive OMP-59R5 12.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15 mg/kg + ETO + CIS Cohort 5: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15mg/kg + ETO + CARB Cohort 6: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and carboplatin AUC of 5 mg/mL•min (Day 1).	P2: Placebo + CIS or CARB Placebo Arm: Active Arm: Subjects receive placebo and etoposide 100 mg/m2 and cisplatin 75 mg/m2 or carboplatin AUC 5 mg/kg \*min	P2: OMP-59R5 15 mg/kg + ETO and CIS or CARB Active Arm: Subjects receive OMP-59R5 15 mg/kg and etoposide 100 mg/m2 and cisplatin 75 mg/m2 or carboplatin AUC 5 mg/kg \*min
Overall Study STARTED	3	3	6	3	6	6	72	73
Overall Study COMPLETED	0	0	0	0	0	0	2	3
Overall Study NOT COMPLETED	3	3	6	3	6	6	70	70

Reasons for withdrawal

Measure	P1B: OMP-59R5 5mg/kg + ETO + CIS Cohort 1: Subjects receive OMP-59R5 5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 7.5 mg/kg + ETO + CIS Cohort 2: Subjects receive OMP-59R5 7.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 10 mg/kg + ETO + CIS Cohort 3: Subjects receive OMP-59R5 10 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3 and cisplatin 80 mg/m2 on Day 1).	P1B: OMP-59R5 12.5 mg/kg + ETO + CIS Cohort 4: Subjects receive OMP-59R5 12.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15 mg/kg + ETO + CIS Cohort 5: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15mg/kg + ETO + CARB Cohort 6: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and carboplatin AUC of 5 mg/mL•min (Day 1).	P2: Placebo + CIS or CARB Placebo Arm: Active Arm: Subjects receive placebo and etoposide 100 mg/m2 and cisplatin 75 mg/m2 or carboplatin AUC 5 mg/kg \*min	P2: OMP-59R5 15 mg/kg + ETO and CIS or CARB Active Arm: Subjects receive OMP-59R5 15 mg/kg and etoposide 100 mg/m2 and cisplatin 75 mg/m2 or carboplatin AUC 5 mg/kg \*min
Overall Study Death	3	2	4	3	5	4	51	51
Overall Study Lost to Follow-up	0	0	0	0	0	1	0	4
Overall Study Withdrawal by Subject	0	1	2	0	0	1	1	1
Overall Study Study Terminated by Sponsor	0	0	0	0	1	0	16	14
Overall Study Other	0	0	0	0	0	0	2	0

Baseline Characteristics

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

Baseline characteristics by cohort

Measure	P1B: OMP-59R5 5mg/kg + ETO + CIS n=3 Participants Cohort 1: Subjects receive OMP-59R5 5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 7.5 mg/kg + ETO + CIS n=3 Participants Cohort 2: Subjects receive OMP-59R5 7.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 10 mg/kg + ETO + CIS n=6 Participants Cohort 3: Subjects receive OMP-59R5 10 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3 and cisplatin 80 mg/m2 on Day 1).	P1B: OMP-59R5 12.5 mg/kg + ETO + CIS n=3 Participants Cohort 4: Subjects receive OMP-59R5 12.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15 mg/kg + ETO + CIS n=6 Participants Cohort 5: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15mg/kg + ETO + CARB n=6 Participants Cohort 6: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and carboplatin AUC of 5 mg/mL•min (Day 1).	P2: OMP-59R5 15 mg/kg + ETO and CIS or CARB n=73 Participants Active Arm: Subjects receive OMP-59R5 15 mg/kg and etoposide 100 mg/m2 and cisplatin 75 mg/m2 or carboplatin AUC 5 mg/kg \*min	P2: Placebo + CIS or CARB n=72 Participants Placebo Arm: Active Arm: Subjects receive placebo and etoposide 100 mg/m2 and cisplatin 75 mg/m2 or carboplatin AUC 5 mg/kg \*min	Total n=172 Participants Total of all reporting groups
Age, Customized Age	68.3 years n=5 Participants	72.3 years n=7 Participants	67.7 years n=5 Participants	64.3 years n=4 Participants	61.0 years n=21 Participants	57.2 years n=10 Participants	65.3 years n=115 Participants	65.4 years n=24 Participants	58.5 years n=42 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	0 Participants n=4 Participants	3 Participants n=21 Participants	3 Participants n=10 Participants	30 Participants n=115 Participants	37 Participants n=24 Participants	77 Participants n=42 Participants
Sex: Female, Male Male	2 Participants n=5 Participants	2 Participants n=7 Participants	4 Participants n=5 Participants	3 Participants n=4 Participants	3 Participants n=21 Participants	3 Participants n=10 Participants	43 Participants n=115 Participants	35 Participants n=24 Participants	95 Participants n=42 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	1 Participants n=115 Participants	1 Participants n=24 Participants	2 Participants n=42 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants	6 Participants n=115 Participants	6 Participants n=24 Participants	13 Participants n=42 Participants
Race (NIH/OMB) White	3 Participants n=5 Participants	3 Participants n=7 Participants	6 Participants n=5 Participants	3 Participants n=4 Participants	6 Participants n=21 Participants	4 Participants n=10 Participants	66 Participants n=115 Participants	64 Participants n=24 Participants	155 Participants n=42 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	1 Participants n=24 Participants	1 Participants n=42 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants
Region of Enrollment United States	3 participants n=5 Participants	3 participants n=7 Participants	6 participants n=5 Participants	3 participants n=4 Participants	6 participants n=21 Participants	6 participants n=10 Participants	73 participants n=115 Participants	72 participants n=24 Participants	172 participants n=42 Participants

PRIMARY outcome

Timeframe: Up to 1 year in absence of unacceptable toxicity or disease progression.

Population: The MTD of OMP-59R5 in combination with etoposide and cisplatin or carboplatin was not reached and the recommended phase 2 dose was determined to be 15 mg/kg every 21-day cycle.

To determine the MTD of tarextumab when administered on Day 1 of each 21 day cycle along with etoposide 100 mg/m2 on Days 1, 2 and 3, and cisplatin 80 mg/m2 or carboplatin area under the curve (AUC) of 5 mg/mL•min on Day 1 in subjects with untreated extensive stage small cell lung cancer. DLT evaluable population includes all subjects who received at least 1 partial dose of OMP-59R5 during the Phase 1b dose escalation portion of the study including the carboplatin cohort and who had completed Day 21 cycle of 1 OMP-59R5 administration or had discontinued due to drug-related toxicity.

Outcome measures

Measure	P1B: OMP-59R5 5mg/kg + ETO + CIS n=3 Participants Cohort 1: Subjects receive OMP-59R5 5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 7.5 mg/kg + ETO + CIS n=3 Participants Cohort 2: Subjects receive OMP-59R5 7.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 10 mg/kg + ETO + CIS n=5 Participants Cohort 3: Subjects receive OMP-59R5 10 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3 and cisplatin 80 mg/m2 on Day 1).	P1B: OMP-59R5 12.5 mg/kg + ETO + CIS n=3 Participants Cohort 4: Subjects receive OMP-59R5 12.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15 mg/kg + ETO + CIS n=6 Participants Cohort 5: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15mg/kg + ETO + CARB n=6 Participants Cohort 6: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and carboplatin AUC of 5 mg/mL•min (Day 1).
Phase 1b: To Determine the Maximum Tolerated Dose (MTD) of OMP-59R5 When Administered With Etoposide and Cisplatin or Carboplatin (Number of Subjects With DLTs)	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Up to 1 year in absence of unacceptable toxicity or disease progression.

The best overall response is defined as the best Investigator-assessed response recorded from the start of the treatment until disease progression in the following order of importance: Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressive Disease (PD), Not Evaluable (NE). Response evaluable population includes subjects who received 1 partial dose of OMP-59R5 and at at least 1 post tumor assessment.

Outcome measures

Measure	P1B: OMP-59R5 5mg/kg + ETO + CIS n=3 Participants Cohort 1: Subjects receive OMP-59R5 5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 7.5 mg/kg + ETO + CIS n=3 Participants Cohort 2: Subjects receive OMP-59R5 7.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 10 mg/kg + ETO + CIS n=5 Participants Cohort 3: Subjects receive OMP-59R5 10 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3 and cisplatin 80 mg/m2 on Day 1).	P1B: OMP-59R5 12.5 mg/kg + ETO + CIS n=3 Participants Cohort 4: Subjects receive OMP-59R5 12.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15 mg/kg + ETO + CIS n=6 Participants Cohort 5: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15mg/kg + ETO + CARB n=6 Participants Cohort 6: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and carboplatin AUC of 5 mg/mL•min (Day 1).
Phase 1b: Overall Response (Response Evaluable Population) Complete Response	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Phase 1b: Overall Response (Response Evaluable Population) Partial Response	3 Participants	2 Participants	4 Participants	2 Participants	5 Participants	4 Participants
Phase 1b: Overall Response (Response Evaluable Population) Stable Disease	0 Participants	1 Participants	1 Participants	1 Participants	0 Participants	1 Participants
Phase 1b: Overall Response (Response Evaluable Population) Progressive Disease	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
Phase 1b: Overall Response (Response Evaluable Population) Not Evaluated	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Phase 1b: Overall Response (Response Evaluable Population) Missing	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: Up to 1 year until disease progression or death.

To determine the improvement in Progression Free Survival (PFS) resulting from the addition of tarextumab to etoposide and platinum therapy (EP) in subjects receiving first-line therapy for extensive stage small cell lung cancer. PFS is based on the Investigator-assessments of tumor response which is defined as the number of days from randomization until death or disease progression as defined by RECIST criteria for the ITT Population.

Outcome measures

Measure	P1B: OMP-59R5 5mg/kg + ETO + CIS n=72 Participants Cohort 1: Subjects receive OMP-59R5 5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 7.5 mg/kg + ETO + CIS n=73 Participants Cohort 2: Subjects receive OMP-59R5 7.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 10 mg/kg + ETO + CIS Cohort 3: Subjects receive OMP-59R5 10 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3 and cisplatin 80 mg/m2 on Day 1).	P1B: OMP-59R5 12.5 mg/kg + ETO + CIS Cohort 4: Subjects receive OMP-59R5 12.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15 mg/kg + ETO + CIS Cohort 5: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15mg/kg + ETO + CARB Cohort 6: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and carboplatin AUC of 5 mg/mL•min (Day 1).
Phase 2: Progression Free Survival (ITT Population) Disease Progression or Death	56 Participants	51 Participants	—	—	—	—
Phase 2: Progression Free Survival (ITT Population) Did not Progress or Die	16 Participants	22 Participants	—	—	—	—

PRIMARY outcome

Timeframe: Up to 1 year in absence of unacceptable toxicity or disease progression

The response rate is the number of subjects per treatment arm who have either a complete response (CR) or partial response (PR) for best overall response (according to RECIST criteria) divided by the number of subjects randomized to the respective arms.

Outcome measures

Measure	P1B: OMP-59R5 5mg/kg + ETO + CIS n=72 Participants Cohort 1: Subjects receive OMP-59R5 5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 7.5 mg/kg + ETO + CIS n=73 Participants Cohort 2: Subjects receive OMP-59R5 7.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 10 mg/kg + ETO + CIS Cohort 3: Subjects receive OMP-59R5 10 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3 and cisplatin 80 mg/m2 on Day 1).	P1B: OMP-59R5 12.5 mg/kg + ETO + CIS Cohort 4: Subjects receive OMP-59R5 12.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15 mg/kg + ETO + CIS Cohort 5: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15mg/kg + ETO + CARB Cohort 6: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and carboplatin AUC of 5 mg/mL•min (Day 1).
Phase 2: Best Overall Tumor Response Based on Investigator Assessment (ITT Population) Progressive Disease	4 Participants	2 Participants	—	—	—	—
Phase 2: Best Overall Tumor Response Based on Investigator Assessment (ITT Population) Complete Response	2 Participants	1 Participants	—	—	—	—
Phase 2: Best Overall Tumor Response Based on Investigator Assessment (ITT Population) Partial Response	49 Participants	49 Participants	—	—	—	—
Phase 2: Best Overall Tumor Response Based on Investigator Assessment (ITT Population) Stable Disease	10 Participants	9 Participants	—	—	—	—
Phase 2: Best Overall Tumor Response Based on Investigator Assessment (ITT Population) Not Evaluable	1 Participants	1 Participants	—	—	—	—
Phase 2: Best Overall Tumor Response Based on Investigator Assessment (ITT Population) No Post-Baseline Tumor Assessment Collected	6 Participants	11 Participants	—	—	—	—

Adverse Events

P1B: OMP-59R5 5mg/kg + ETO + CIS

Serious events: 1 serious events

Other events: 3 other events

Deaths: 3 deaths

P1B: OMP-59R5 7.5 mg/kg + ETO + CIS

Serious events: 2 serious events

Other events: 3 other events

Deaths: 2 deaths

P1B: OMP-59R5 10 mg/kg + ETO + CIS

Serious events: 6 serious events

Other events: 6 other events

Deaths: 4 deaths

P1B: OMP-59R5 12.5 mg/kg + ETO + CIS

Serious events: 1 serious events

Other events: 3 other events

Deaths: 3 deaths

P1B: OMP-59R5 15 mg/kg + ETO + CIS

Serious events: 0 serious events

Other events: 6 other events

Deaths: 5 deaths

P1B: OMP-59R5 15mg/kg + ETO + CARB

Serious events: 3 serious events

Other events: 6 other events

Deaths: 4 deaths

P2: Placebo + CIS or CARB

Serious events: 29 serious events

Other events: 68 other events

Deaths: 51 deaths

P2: OMP-59R5 15 mg/kg + ETO and CIS or CARB

Serious events: 37 serious events

Other events: 69 other events

Deaths: 51 deaths

Serious adverse events

Measure	P1B: OMP-59R5 5mg/kg + ETO + CIS n=3 participants at risk Cohort 1: Subjects receive OMP-59R5 5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 7.5 mg/kg + ETO + CIS n=3 participants at risk Cohort 2: Subjects receive OMP-59R5 7.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 10 mg/kg + ETO + CIS n=6 participants at risk Cohort 3: Subjects receive OMP-59R5 10 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3 and cisplatin 80 mg/m2 on Day 1).	P1B: OMP-59R5 12.5 mg/kg + ETO + CIS n=3 participants at risk Cohort 4: Subjects receive OMP-59R5 12.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15 mg/kg + ETO + CIS n=6 participants at risk Cohort 5: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15mg/kg + ETO + CARB n=6 participants at risk Cohort 6: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and carboplatin AUC of 5 mg/mL•min (Day 1).	P2: Placebo + CIS or CARB n=68 participants at risk Placebo Arm: Active Arm: Subjects receive placebo and etoposide 100 mg/m2 and cisplatin 75 mg/m2 or carboplatin AUC 5 mg/kg \*min	P2: OMP-59R5 15 mg/kg + ETO and CIS or CARB n=69 participants at risk Active Arm: Subjects receive OMP-59R5 15 mg/kg and etoposide 100 mg/m2 and cisplatin 75 mg/m2 or carboplatin AUC 5 mg/kg \*min
Infections and infestations Pneumonia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	17.4% 12/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Sepsis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Clostridium difficile colitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Clostridium difficile infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Diverticulitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Pneumonia legionella	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Salmonellosis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Bronchitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Device related infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Lung abscess	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Diarrhoea	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Gastric haemorrhage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Intestinal haemorrhage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Pancreatitis acute	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Vomiting	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Anaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Pancytopenia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Pneumothorax spontaneous	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.4% 5/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Gout	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hypercreatininaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Electrolyte imbalance	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Cardiac arrest	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Atrial fibrillation	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Myocardial infarction	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Acute coronary syndrome	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Acute myocardial infarction	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Myocardial ischaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Chest pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Fatigue	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Non-cardiac chest pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Asthenia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Pyrexia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer extensive stage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to central nervous system	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Lipase increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Spinal cord compression	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Convulsion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Hepatic encephalopathy	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Syncope	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Partial seizures	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Psychiatric disorders Depression	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Psychiatric disorders Confusional state	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Spinal compression fracture	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Fall	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Hypovolaemic shock	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Deep vein thrombosis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Embolism	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Hypotension	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Orthostatic hypotension	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Renal failure acute	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.

Other adverse events

Measure	P1B: OMP-59R5 5mg/kg + ETO + CIS n=3 participants at risk Cohort 1: Subjects receive OMP-59R5 5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 7.5 mg/kg + ETO + CIS n=3 participants at risk Cohort 2: Subjects receive OMP-59R5 7.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 10 mg/kg + ETO + CIS n=6 participants at risk Cohort 3: Subjects receive OMP-59R5 10 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3 and cisplatin 80 mg/m2 on Day 1).	P1B: OMP-59R5 12.5 mg/kg + ETO + CIS n=3 participants at risk Cohort 4: Subjects receive OMP-59R5 12.5 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15 mg/kg + ETO + CIS n=6 participants at risk Cohort 5: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and cisplatin 80 mg/m2 (Day 1).	P1B: OMP-59R5 15mg/kg + ETO + CARB n=6 participants at risk Cohort 6: Subjects receive OMP-59R5 15 mg/kg (administered on Day 1 of each 21-day cycle) along with etoposide 100 mg/m2 (Days 1, 2, and 3) and carboplatin AUC of 5 mg/mL•min (Day 1).	P2: Placebo + CIS or CARB n=68 participants at risk Placebo Arm: Active Arm: Subjects receive placebo and etoposide 100 mg/m2 and cisplatin 75 mg/m2 or carboplatin AUC 5 mg/kg \*min	P2: OMP-59R5 15 mg/kg + ETO and CIS or CARB n=69 participants at risk Active Arm: Subjects receive OMP-59R5 15 mg/kg and etoposide 100 mg/m2 and cisplatin 75 mg/m2 or carboplatin AUC 5 mg/kg \*min
Gastrointestinal disorders Diarrhoea	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	83.3% 5/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	100.0% 3/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	83.3% 5/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	100.0% 6/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.8% 23/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	76.8% 53/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Nausea	100.0% 3/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 4/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 4/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 4/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	64.7% 44/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	52.2% 36/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Vomiting	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 4/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.2% 11/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	31.9% 22/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Constipation	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	41.2% 28/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	15.9% 11/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	11.8% 8/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Gastrooesophageal reflux disease	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.8% 6/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	10.1% 7/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Dyspepsia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Flatulence	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Abdominal distension	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Anorectal discomfort	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Ascites	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Dysphagia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Basophil count increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Gingival bleeding	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Oral pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Pancreatitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Pancreatitis acute	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Perianal erythema	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Toothache	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Umbilical hernia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Decreased appetite	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	23.5% 16/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	37.7% 26/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hypercreatininaemia	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 4/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hypomagnesaemia	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	22.1% 15/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	21.7% 15/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Dehydration	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	20.6% 14/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	24.6% 17/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.4% 5/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	34.8% 24/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hypocalcaemia	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	11.6% 8/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hyponatraemia	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	13.2% 9/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	14.5% 10/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	13.0% 9/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Electrolyte imbalance	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Fluid retention	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Gout	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hypovolaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Anaemia	100.0% 3/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	100.0% 3/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 4/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	55.9% 38/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.7% 35/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Thrombocytopenia	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 4/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 4/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	17.6% 12/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	58.0% 40/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Neutropenia	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	47.1% 32/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	31.9% 22/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.2% 5/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Leukopenia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	14.7% 10/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.7% 6/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Leukocytosis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Pancytopenia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Fatigue	100.0% 3/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	100.0% 3/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	83.3% 5/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	63.2% 43/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	62.3% 43/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Oedema peripheral	100.0% 3/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	19.1% 13/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	11.6% 8/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Pyrexia	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	11.8% 8/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.2% 5/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Asthenia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	10.3% 7/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	14.5% 10/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Mucosal inflammation	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Catheter site erythema	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Catheter site pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Chest discomfort	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Chest pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	13.0% 9/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Chills	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.7% 6/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Device occlusion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Generalised oedema	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Oedema	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Headache	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	10.3% 7/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	11.6% 8/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Dizziness	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	19.1% 13/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	20.3% 14/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Dysgeusia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	10.3% 7/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	18.8% 13/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Neuropathy peripheral	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.4% 5/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Migraine	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Balance disorder	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Lethargy	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Paraesthesia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Parosmia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Partial seizures	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.4% 5/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Sciatica	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Tremor	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Vocal cord paralysis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	26.5% 18/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	30.4% 21/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	25.0% 17/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	20.3% 14/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.4% 5/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Productive cough	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.4% 5/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.7% 6/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Pleural effusion	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Blood alkaline phosphatase increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	13.0% 9/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Laryngeal haemorrhage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Sinus congestion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Alopecia	100.0% 3/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	66.7% 4/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	39.7% 27/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	39.1% 27/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.7% 6/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Rash	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.2% 5/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.2% 5/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Rash erythematous	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Scab	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Skin ulcer	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Weight decreased	66.7% 2/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.2% 11/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	26.1% 18/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Lip dry	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Blood bilirubin decreased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Blood cholesterol increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Blood urea increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Electrocardiogram QT prolonged	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Lymphocyte count decreased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Weight increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Pneumonia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	18.8% 13/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Upper respiratory tract infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Candidiasis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Corneal infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Eye infection	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Fungal infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Gastroenteritis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Influenza	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Oral candidiasis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Sepsis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Urinary tract infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.2% 11/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	11.6% 8/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Vulval abscess	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Back pain	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	14.7% 10/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	13.0% 9/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Hypercreatinaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	14.7% 10/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.8% 6/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.2% 5/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Limb discomfort	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	10.3% 7/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Pain in jaw	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Psychiatric disorders Anxiety	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	50.0% 3/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	10.3% 7/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.2% 5/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Psychiatric disorders Depression	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	10.1% 7/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Psychiatric disorders Confusional state	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Psychiatric disorders Insomnia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	11.8% 8/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	18.8% 13/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Hypotension	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	14.7% 10/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.2% 5/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Hypertension	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.8% 6/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.7% 6/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Embolism	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Ear and labyrinth disorders Tinnitus	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.4% 5/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Ear and labyrinth disorders Ear discomfort	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Ear and labyrinth disorders Ear pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Ear and labyrinth disorders Hypoacusis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Renal failure acute	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Proteinuria	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Haematuria	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Renal failure	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Atrial fibrillation	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Tachycardia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Fall	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Laceration	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Immune system disorders Drug hypersensitivity	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to central nervous system	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 2/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Eye disorders Eye pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Eye disorders Vision blurred	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	16.7% 1/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Reproductive system and breast disorders Scrotal oedema	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Reproductive system and breast disorders Testicular pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	33.3% 1/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Stomatitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	15.9% 11/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Haematochezia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Abdominal hernia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Dry mouth	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.8% 6/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Enterocolitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Epigastric discomfort	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Faecal incontinence	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Gastric haemorrhage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Intestinal haemorrhage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Lower gastrointestinal haemorrhage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Oral discomfort	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Abdominal tenderness	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Colitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Gastritis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Haemorrhoids	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Hiatus hernia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Lip swelling	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Loose tooth	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Gastrointestinal disorders Oesophageal spasm	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Malaise	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Infusion site irritation	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Non-cardiac chest pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Extravasation	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Facial pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Infusion site extravasation	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Injection site reaction	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Face oedema	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Gait disturbance	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
General disorders Peripheral swelling	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.8% 6/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	10.1% 7/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hypernatraemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Increased appetite	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Metabolism and nutrition disorders Iron deficiency	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Chronic respiratory failure	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Diaphragmalgia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Haemothorax	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Laryngeal inflammation	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Pleuritic pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Respiratory tract congestion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	10.3% 7/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Pneumothorax spontaneous	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Mediastinal disorder	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Pulmonary pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Respiratory, thoracic and mediastinal disorders Rales	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Candida infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.7% 6/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Clostridium difficile infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Diverticulitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Folliculitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Lung infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Bronchitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Cellulitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Clostridium difficile colitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Furuncle	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Helicobacter infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Mucosal infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Nasopharyngitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Oral herpes	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Otitis media	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Pneumonia legionella	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Salmonellosis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Skin infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Tooth infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Vaginal infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Viral infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Device related infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Ear infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Hordeolum	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Lung abscess	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Nail infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Oral infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Oropharyngeal candidiasis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Sinusitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Staphylococcal infection	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Infections and infestations Vaginal cellulitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Alanine aminotransferase increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.4% 5/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.7% 6/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Aspartate aminotransferase increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.8% 4/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Blood bilirubin increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations White blood cell count increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Activated partial thromboplastin time prolonged	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Blood lactate dehydrogenase increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Blood lactic acid increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Blood urea decreased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Electrocardiogram ST segment abnormal	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Electrocardiogram T wave abnormal	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Haematocrit decreased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Hepatic enzyme increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations International normalised ratio increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Lipase increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Liver function test abnormal	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Lymphocyte count increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Platelet count increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Red blood cell count decreased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Urine bilirubin increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Urine ketone body present	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Vitamin D decreased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Blood creatine phosphokinase increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Blood glucose increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Blood sodium increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Electrocardiogram abnormal	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Protein urine present	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Troponin increased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Investigations Urine output decreased	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	7.2% 5/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Pain of skin	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Acne	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Dermatitis contact	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Hyperkeratosis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Petechiae	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Skin atrophy	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Dermatitis bullous	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Erythema nodosum	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Hypohidrosis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Rash follicular	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	10.1% 7/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	5.9% 4/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Gouty arthritis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	8.8% 6/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Haemarthrosis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Osteoporosis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Musculoskeletal and connective tissue disorders Spinal pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Hypoaesthesia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Convulsion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Dizziness postural	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Dysarthria	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Hemiparesis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Memory impairment	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Spinal cord compression	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Syncope	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Transient ischaemic attack	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Ageusia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Ataxia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Brain oedema	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Hepatic encephalopathy	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Presyncope	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Restless legs syndrome	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Nervous system disorders Somnolence	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Deep vein thrombosis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Flushing	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Hypovolaemic shock	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Orthostatic hypotension	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Vascular disorders Phlebitis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Cardiac arrest	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Atrial flutter	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Bradycardia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Conduction disorder	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Myocardial infarction	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Sinus tachycardia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Acute coronary syndrome	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Acute myocardial infarction	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Angina pectoris	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Myocardial ischaemia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Palpitations	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Cardiac disorders Supraventricular extrasystoles	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Dysuria	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Incontinence	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Nephrolithiasis	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Pollakiuria	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Renal colic	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Urinary hesitation	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Urinary tract obstruction	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Urinary incontinence	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Renal and urinary disorders Urinary tract pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Contusion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Incision site pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Thermal burn	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Vascular access complication	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Femur fracture	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Foot fracture	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Pubis fracture	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Rib fracture	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Injury, poisoning and procedural complications Spinal compression fracture	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Ear and labyrinth disorders Vertigo	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.3% 3/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Ear and labyrinth disorders Deafness	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Ear and labyrinth disorders Cerumen impaction	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Ear and labyrinth disorders Deafness bilateral	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Ear and labyrinth disorders Ear congestion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Ear and labyrinth disorders Otorrhoea	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Ear and labyrinth disorders Vestibular disorder	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Eye disorders Dry eye	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Eye disorders Visual acuity reduced	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Eye disorders Blindness unilateral	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Eye disorders Diplopia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Eye disorders Eye pruritus	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Immune system disorders Seasonal allergy	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Immune system disorders Hypersensitivity	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Reproductive system and breast disorders Menstruation irregular	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Reproductive system and breast disorders Nipple pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Reproductive system and breast disorders Vulvovaginal erythema	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Reproductive system and breast disorders Vulvovaginal pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	4.4% 3/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Endocrine disorders Adrenal insufficiency	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.4% 1/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	2.9% 2/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer extensive stage	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/3 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/6 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	1.5% 1/68 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.	0.00% 0/69 • Adverse event and serious adverse event data are collected from the time of first administration of OMP-59R5, etoposide or platinum therapy up to 4 weeks after the last administration OMP-59R5, etoposide or platinum therapy, whichever is discontinued last but but before the initiation of a new anti-cancer therapy. All cause mortality was collected every 3 months until death, loss to follow-up or study termination by the sponsor (up to 35 months). P1: All cause mortality was assessed on the ITT population which was comprised of all subjects who receive at least one partial dose of OMP-59R5. Serious and non-serious AEs were assessed on the ITT population. P2: All cause mortality was assessed on the ITT population which was comprised of all randomized subjects. Serious and non-serious AEs were assessed on the Safety Population which was defined as all subjects who received one partial dose of OMP-59R5 or placebo.

Additional Information

Manager, Regulatory Affairs

OncoMed Pharmaceuticals, Inc.

Phone: 6509958322

Email: imran.chaudhry@oncomed.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place